Table 3.
Cases | All n (%) |
TBx n (%) |
SBx n (%) |
TBx/SBx n (%) |
---|---|---|---|---|
1 Biopsy negative | 155 (57.0%) | 183 (67.3%) | 182 (66.9%) | 155 (57.0%) |
1 CDR for ciPCa | 43 (15.8%) | 28 (10.3%) | 29 (10.7%) | 43 (15.8%) |
1 CDR for csPCa | 74 (27.2%) | 61 (22.4%) | 61 (22.4%) | 74 (27.2%) |
1 False negative PCa | 28 (10.3%) | 27 (9.9%) | 0 (0%) | |
2 Sensitivity for csPCa | 82.4% | 82.4% | 100% | |
Specificity for csPCa | 85.% | 85.8% | 78.3% |
1 Percentage refers to the entire cohort (n = 272). 2 False negative includes biopsy negative plus ciPCa; since all diagnosed csPCa are derived from either TBx or SBx, the sensitivity of the combined TBx/SBx is 100%.